Effect of Route of Administration of Human Recombinant Factor VIII on Its Immunogenicity in Hemophilia A Mice

Factor VIII is a multi-domain glycoprotein and is an essential cofactor in the blood coagulation cascade. Its deficiency or dysfunction causes Hemophilia A, a bleeding disorder. Replacement using exogenous recombinant Factor VIII (FVIII) is the first line of therapy for Hemophilia A. Immunogenicity,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of pharmaceutical sciences 2009-12, Vol.98 (12), p.4480-4484
Hauptverfasser:	Peng, Aaron, Gaitonde, Puneet, Kosloski, Matthew P., Miclea, Razvan D., Varma, Prashant, Balu-Iyer, Sathy V.
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Antibodies Antibodies - analysis Antibodies, Blocking - pharmacology Biological and medical sciences Bleeding Blood coagulation CHO Cells Coagulation factors Cofactors Cricetinae Cricetulus Enzyme-Linked Immunosorbent Assay Factor VIII - administration & dosage Factor VIII - immunology Factor VIII - pharmacology General pharmacology Glycoproteins Glycosylation Hemophilia Hemophilia A Hemophilia A - drug therapy Hemophilia A - metabolism Humans Immunogenicity inhibitor development Injections, Intravenous Injections, Subcutaneous Medical sciences Mice Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments route of administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!